

Tentative Agenda for Spring 2013 CTEP EDD Meeting, April 22 – 23, 2013

Monday, April 22, 2013

8:30 AM Welcome/ Introduction John Wright IDB, CTEP

CTEP Early Phase Trials Status Update Session

Phase I Clinical Trial Status Update Session

Moderators: Alice Chen, Pam Harris IDB, CTEP, NCI

8:35 AM– 8:50 AM: COG phase I study of pazopanib in pediatric patients with solid tumors

Julia Glade-Bender, Columbia University

8:50 AM – 9:05 AM: A Phase I trial of entinostat and high-dose IL-2 in renal cell carcinoma patients

Roberto Pili Roswell Park Memorial Institute

9:05 AM – 9:20 AM: A Phase I trial of cilengitide and paclitaxel in patients with solid tumors.

Tufia Haddad Mayo Clinic

9:20 AM – 9:35 AM: Phase I combination study of alvocidib and bortezomib in lymphoma and myeloma patients.

Beata Holkova, Virginia Commonwealth University

9:35 AM – 9:50 AM: A Phase I study of temozolomide and veliparib in acute myelogenous leukemia patients

Ivana Gojo, JHU

9:50 AM– 10:10 AM: Panel discussion

10:10 AM – 10:30 AM: Break

Phase II Clinical Update Session

Moderator: *Austin Doyle, Richard Piekarz IDB, CTEP, NCI*

**10:30 AM – 10:45 AM: Phase II, PIK3CA Mutation Stratified Trial of MK-2206 in
Recurrent Endometrial Cancer
Andrea Myers, Dana Farber Cancer Institute**

**10:45 AM – 11:00 AM: Phase II study of vorinostat in the treatment of adenoid cystic
carcinoma patients.**

Priscila Goncalves Karmanos Cancer Center

**11:00 AM – 11:15 AM: Phase II trial of alvocidib plus oxaliplatin with or without 5-FU
and leucovorin in patients with relapsed/refractory germ cell tumors.**

Darren Feldman Memorial Sloan-Kettering Cancer Center

**11:15 AM – 11:30 AM: Phase II Study of temsirolimus +/- Cetuximab in patients with
Cetuximab-resistant squamous cell cancer of the Head and Neck**

Tanguy Siewert, University of Chicago

11:30 AM – 11:50 PM: Panel Discussion

**11:50 PM – 1:30 Lunch
UO1/NO1 Meeting (closed)**

CTEP-sponsored Investigational Agent Trials in AML:

Moderator: Naoko Takebe, Richard Little, CTEP, NCI

**1:30 PM – 1:50 PM: Tipifarnib for treatment of patients with Acute Myelogenous
Leukemia in Remission**

Selina Luger, University of Pennsylvania

1:50 PM – 2:10 PM: Tipifarnib in Newly-Diagnosed Acute Myelogenous Leukemia with patient selection using a 2-Gene Expression Signature Ratio

Jeffrey Lancet, Moffit Cancer Center

2:10 PM – 2:30 PM: ECOG phase II trial Comparing Three Different Chemotherapy Combination Regimens in Patients with Relapsed or Refractory Acute Leukemia

Mark Litzow, Mayo Clinic

2:30 PM – 2:50 PM Randomized Phase II Trial of Timed-Sequential Therapy with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus 7+3 for Adults Ages 70 Years and Under with Newly Diagnosed AML

Joshua Zeidner, Johns Hopkins University

2:50 PM – 3:10 PM: Break

3:10 PM– 3:30 PM CALGB Study of Bortezomib, Daunorubicin and Cytarabine for Older Patients with Previously Untreated Acute Myeloid Leukemia.

Eyal Attar, Dana-Farber Cancer Center

3:30 PM– 3:50 PM A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy plus Dasatinib and Continuation Therapy with Dasatinib Alone in Newly-Diagnosed Patients with Core Binding Factor Acute Myelogenous Leukemia

Guido Marcucci, OSU

3:50 PM – 4:15 PM Discussion

Tuesday, March 23, 2013

Education Session: Resistance to Targeted Therapies: Mechanisms and Clinical Implications

***Moderator: Jeffrey Moscow, IDB, CTEP
Elad Sharon, IDB, CTEP***

**8:30 AM – 9:10 AM: Resistance to EGFR Inhibitors
Katerina Politi Yale University**

**9:10 AM – 9:50 AM: Overcoming Resistance to mutant BRAF inhibitors
Keith Flaherty Massachusetts General Hospital**

**9:50 AM – 10:30 AM: Development of Resistance to JAK Inhibitors
Priya Koppikar Memorial Sloan-Kettering Cancer Center**

10:30 AM – 10:45 AM: Break

10:45 AM – 11:25 AM: Mechanisms of Resistance to Inhibitors of the PI3K/AKT/mTOR signaling pathway.

**George Thomas, University of Cincinnati, USA and
ICO/IDIBELL, Barcelona, Spain**

**11:25 AM – 12:05 AM Development of resistance to ALK inhibitors
Robert Doebele, University of Colorado**

12:05 PM – 12:25 PM: Discussion

